These include: Nausea (very common), typically most pronounced in the first few weeks Vomiting and diarrhoea (common), which can contribute to dehydration Constipation (common), which may require dietary adjustments Abdominal pain and bloating (common), related to delayed gastric emptying Reduced appetite (very common), which whilst therapeutically beneficial for weight loss, may lead to inadequate nutrition if extreme These effects usually diminish over time as tolerance develops
The double-blind clinical trial of 1961 adults with overweight or obesity without diabetes found that the average weight loss after 68 weeks was about 15 percent of body weight for those given semaglutide versus only about 2.5 percent for those taking the placebo
Its a hormone the body naturally produces in the gut that helps regulate blood sugar, appetite, and insulin release
Before weight loss, some older adults already meet the clinical criteria for Sarcopenic Obesity, or Obesity co-incident with Sarcopenia
CNN recently reported growing scientific and regulatory attention surrounding ibogaine research, particularly in areas involving opioid addiction and treatment-resistant mental health conditions
